NCI Deputy Director James Doroshow, MD, will participate in a forum discussion titled, “Regulatory and Operational Implications of Cancer Clinical Trial Changes During COVID-19.”
Join this session on Monday, July 20, 1:05-2:05 p.m. EDT
|
Cancer researcher and Director of NCI's Center for Cancer Genomics, Louis M. Staudt, MD, PhD, will present his session, "Inhibition of Bruton Tyrosine Kinase in Patients with Severe COVID-19," during the Symposium on Cancer Drug Repurposing to Treat COVID-19.
Join this session on Monday, July 20, 2:20-4:35 p.m. EDT
|
.png)
No hay comentarios:
Publicar un comentario